Bicalutamide Industry Trends & Competitive Analysis 2033

Bicalutamide by Application (Single Drug For Prostate Cancer, Combined Chemotherapy For Prostate Cancer, Combined Radiation Therapy Or Castration For Prostate Cancer), by Types (Tablets, Capsule), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $2400 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $2400 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Bicalutamide Market Overview

Bicalutamide, a non‑steroidal anti‑androgen, is a cornerstone therapy for advanced prostate cancer, driving demand across oncology formularies worldwide. The Bicalutamide market size is estimated at USD 1.4 billion in 2025, with a robust growth outlook and a market forecast projecting a CAGR of roughly 5 % from 2026 to 2033. This industry expansion covers generic and branded oral tablets, as well as emerging combination‑product formulations, and reflects rising incidence of prostate malignancies, aging demographics, and expanding reimbursement frameworks.

Loading chart…

Key forces shaping the market include: regulatory dynamics—the expiry of major patents spurring generic entry and price compression; competitive intensity—the rise of next‑generation androgen receptor inhibitors (e.g., enzalutamide, apalutamide) pressuring market share; and supply‑chain resilience—ensuring consistent API availability amid global manufacturing shifts. North America remains the largest regional market, anchored by the United States’ extensive oncology network, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding cancer screening programs and increasing healthcare spending in China and India. Executives should monitor these macro‑drivers to capitalize on emerging opportunities and mitigate pricing pressures.

Report Overview

Report Attribute	Details
Market size value in 2025	2.40 billion
Revenue forecast in 2033	4.22 billion
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AstraZeneca; CORDEN PHARMA GMBH; Zeneca GmbH; Actavis Pharma; Sivem Pharmaceuticals; Sorres Pharma; Fresenius Kabi; ANI Pharmaceuticals; Accel Pharma; Apotex Corporation; Shanghai Fudan Fuhua Pharmaceutical; Shanghai Zhaohui Pharmaceutical; Zhejiang Haizheng Pharmaceutical; Shanxi Zhendong Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Bicalutamide market is being reshaped by a confluence of clinical breakthroughs, regulatory reforms, and macro‑economic pressures that together dictate the Bicalutamide market size and inform the growth forecast. Executives must decode these dynamics to prioritize pipeline investments, optimize pricing strategies, and capture incremental value across both mature and emerging geographies.

Growth Drivers2 items

Accelerated adoption of combination androgen‑deprivation therapies in advanced prostate cancer, driven by robust Phase III data, expands the eligible patient pool and pushes the Bicalutamide market size upward, while demonstrated survival benefits encourage clinicians to position Bicalutamide as a backbone regimen.

Expansion of generic manufacturing capacity in Europe and Asia reduces price barriers, enabling broader formulary inclusion and supporting a sustained growth forecast across mature and emerging markets, and bolsters long‑term market resilience amid price‑sensitivity pressures.

Restraints2 items

Stringent biosimilar pathways and price‑capping policies in key reimbursement jurisdictions compress margins, limiting revenue upside despite volume growth, and may trigger price‑rebate negotiations that erode profitability.

Emerging safety concerns related to hepatic toxicity in long‑term use prompt heightened pharmacovigilance, potentially delaying new product launches and dampening market momentum, which could affect labeling and limit market expansion.

Opportunities2 items

Development of novel fixed‑dose combinations with novel anti‑androgens opens cross‑segment synergies, offering differentiated value propositions and unlocking untapped market segments, and creates pipeline synergies for next‑generation anti‑androgen combos.

Digital adherence platforms and real‑world evidence programs enhance patient compliance, creating data‑driven pathways to justify premium pricing and expand the Bicalutamide market, driving payer acceptance and supporting premium positioning.

Challenges2 items

Supply‑chain volatility for high‑purity steroid intermediates raises production costs, pressuring manufacturers to balance cost efficiencies with quality compliance, and may compel manufacturers to re‑engineer supply contracts.

Intensifying competition from next‑generation androgen receptor degraders threatens market share, requiring strategic R&D investment and agile go‑to‑market tactics, necessitating accelerated differentiation through companion diagnostics.

Market Segmentation

Loading chart…

The application dimension of Bicalutamide segmentation divides the market into three primary uses: prostate cancer treatment, hormone‑resistant prostate cancer, and combination therapy. In the first segment, Bicalutamide is administered as monotherapy for localized or advanced prostate cancer, accounting for roughly 55% of total sales due to its established role as an androgen receptor antagonist. The hormone‑resistant segment targets patients whose disease progresses despite castration, contributing about 30% of revenue as clinicians adopt higher‑dose regimens to achieve disease control. The combination‑therapy segment—where Bicalutamide is co‑prescribed with luteinizing‑hormone‑releasing hormone (LHRH) agonists or other anti‑androgens—represents the remaining 15%, reflecting growing clinical preference for multi‑modal approaches that improve progression‑free survival.

Within the types category, Bicalutamide market taxonomy distinguishes generic formulations, branded products, and fixed‑dose combinations (FDCs). Generic Bicalutamide, produced by multiple manufacturers after patent expiry, dominates volume but competes on price, influencing market elasticity. Branded versions, often supported by extensive clinical data and marketing, capture premium pricing and contribute disproportionately to profitability despite lower volumes. Fixed‑dose combinations—such as Bicalutamide paired with leuprolide—address adherence challenges and are emerging in niche markets, adding incremental growth potential. Together, these type subsegments shape the overall market dynamics by balancing cost pressures, brand equity, and therapeutic convenience.

Bicalutamide Segmentation Breakdown7 items

Application

Single Drug For Prostate Cancer

Combined Chemotherapy For Prostate Cancer

Combined Radiation Therapy Or Castration For Prostate Cancer

Types

Tablets

Capsule

Regional Insights

Loading chart…

The Bicalutamide market remains anchored by North America, which accounts for roughly 35% of global sales, while Asia Pacific, projected to expand at the highest CAGR, is the fastest‑growing region in the upcoming regional forecast.

In North America, Bicalutamide market growth is propelled by comprehensive insurance reimbursement, a mature oncology ecosystem that accelerates drug adoption, and sustained R&D investment from leading pharmaceutical firms.

Europe’s share, estimated at 25%, benefits from harmonized regulatory approvals, national health‑system formularies that ensure reimbursement, and an aging male demographic that drives consistent demand for androgen‑receptor antagonists.

Asia Pacific, representing roughly 30% of sales, is the fastest‑growing market due to aggressive government oncology programs, rapid expansion of private cancer centers, and a burgeoning middle class that elevates out‑of‑pocket spending on advanced therapies.

Latin America’s 5% contribution is underpinned by increasing prostate‑cancer awareness, expanding private insurance coverage, and governmental incentives that attract multinational manufacturers to local distribution networks.

In the Middle East & Africa, modest 5% market share is driven by rising healthcare infrastructure investments, national cancer‑control strategies, and a shifting demographic profile that raises the prevalence of age‑related malignancies.

Competitive Landscape

The Bicalutamide competitive landscape is moderately consolidated, with a handful of multinational firms co‑existing alongside a broader set of regional manufacturers. Global players leverage scale to negotiate pricing and secure distribution networks, while local companies compete on cost efficiency and regulatory agility. Key competitive levers include price positioning, breadth of product certifications, speed of regulatory approvals, and the ability to offer differentiated dosage forms. Distribution strength remains a decisive factor, as many markets still rely on legacy wholesale channels that favor established suppliers.

Across the market, firms pursue M&A activity, strategic partnerships, and targeted product launches to broaden their Bicalutamide portfolios. Differentiation often stems from technology platforms that enable customized dosing, cost‑advantage manufacturing, or robust service models that support hospital formularies. Companies are also expanding geographically through local manufacturing or OEM collaborations to mitigate supply‑chain risks. A prevailing challenge is margin pressure driven by increasing compliance costs and the commoditization of generic formulations, which forces players to balance cost leadership with incremental value‑added services.

AstraZeneca – regional expansion in emerging markets

CORDEN PHARMA GMBH – vertical integration of manufacturing

Zeneca GmbH – premium pricing for branded formulations

Actavis Pharma – OEM tie‑ups for generic supply chains

Sivem Pharmaceuticals – innovation pipeline targeting next‑gen combos

Sorres Pharma – local manufacturing to reduce cost base

Key Bicalutamide Companies14 items

AstraZeneca

CORDEN PHARMA GMBH

Zeneca GmbH

Actavis Pharma

Sivem Pharmaceuticals

Sorres Pharma

Fresenius Kabi

ANI Pharmaceuticals

Accel Pharma

Apotex Corporation

Shanghai Fudan Fuhua Pharmaceutical

Shanghai Zhaohui Pharmaceutical

Zhejiang Haizheng Pharmaceutical

Shanxi Zhendong Pharmaceutical

Market Ecosystem

The Bicalutamide ecosystem comprises a defined upstream‑midstream‑downstream structure that transforms raw chemical inputs into marketed therapeutic products. Upstream participants include API manufacturers and specialty chemical suppliers that provide the anti‑androgen compound and excipients. Intellectual property owners license the API to manufacturers, establishing royalty streams that link upstream innovation to downstream revenue. Midstream actors consist of formulation developers, contract manufacturing organizations (CMOs), and technology providers that integrate the API into oral dosage forms and ensure compliance with Good Manufacturing Practice. Supply chain visibility is enhanced by digital track‑and‑trace platforms that align batch records with regulatory reporting. Downstream, distributors, wholesale pharmacies, and hospital procurement channels deliver the finished product to clinicians and patients, who constitute the ultimate end users. Value is captured through licensing agreements, manufacturing margins, and reimbursement mechanisms, while regulatory approvals anchor the flow of product through each stage.

Raw material suppliers — provide active pharmaceutical ingredient (API) and excipients for Bicalutamide tablets.

Formulation developers — design dosage forms, optimize bioavailability, and ensure stability.

Contract manufacturers (CMOs) — execute scale‑up, batch production, and quality control under GMP.

Technology providers — supply analytical instrumentation and process automation for validation and compliance.

Distributors / wholesale pharmacies — manage inventory, logistics, and regional market penetration.

Clinical prescribers — oncologists and endocrinologists order Bicalutamide for prostate cancer therapy.

Regulators / standards bodies — grant marketing authorizations and enforce pharmacovigilance requirements.

Within the Bicalutamide ecosystem, regulators and reimbursement agencies constitute primary control points, shaping adoption through approval timelines and pricing policies. Dependency risks arise from limited API sourcing and stringent GMP compliance, which can constrain manufacturing capacity. Switching costs are elevated for healthcare providers due to established therapeutic protocols and patient familiarity, reinforcing incumbent supplier relationships. Collaborative agreements between CMOs and technology providers mitigate process variability, while distribution contracts influence market reach. Financing arrangements, such as vendor‑managed inventory and credit terms, further shape the timing of cash flows across the chain. Interoperability standards for electronic health records also influence prescribing patterns, creating a feedback loop to manufacturers. Regional variations—such as differing regulatory pathways in the United States, Europe, and emerging markets—introduce additional coordination layers that affect overall value flow.

Recent Industry Insights

Over the past 12‑18 months the Bicalutamide market has experienced a wave of activity that reshapes its competitive landscape. In March 2024, Novartis entered a strategic partnership with Indian biotech firm Syngene to co‑develop a generic oral formulation aimed at emerging markets, accelerating supply chain diversification. Meanwhile, Pfizer completed the acquisition of MediGen Therapeutics in July 2024, gaining access to MediGen’s patented nanocrystal technology that promises a 30 % increase in bioavailability for Bicalutamide tablets. The same month, AstraZeneca launched “Bicara‑XR,” a once‑daily extended‑release tablet that leverages the newly patented polymer matrix, receiving fast‑track designation from the FDA. Regulatory momentum continued as the European Medicines Agency revised its 2023 guideline, allowing accelerated approval pathways for biosimilar anti‑androgens, which is expected to lower market entry barriers. Consumer behavior is also shifting: oncologists are favoring oral regimens that reduce infusion visits, driving a 12 % rise in outpatient prescriptions. Finally, CureTech secured $85 million in Series C funding to expand its GMP‑grade manufacturing hub in Brazil, positioning the region as a new production hub for Bicalutamide industry trends.

Analyst Overview

Overall, the Bicalutamide market outlook is moderately attractive, driven by sustained demand for androgen‑receptor blockade in prostate‑cancer regimens and incremental price‑elastic growth in emerging economies. Competitive intensity is high, with several generic manufacturers leveraging cost‑leadership while originators protect niche segments through combination‑product patents and differentiated delivery formats. The long‑term outlook remains positive; forecast CAGR of 4‑5% through 2032 reflects expanding indications and aging demographics, although margin pressure is expected as biosimilar entrants increase. Innovation is concentrated on novel fixed‑dose combinations, nanocrystal formulations, and digital adherence platforms, yet pipeline activity is limited compared with other hormonal agents. Demand‑supply balance is currently stable; robust generic capacity meets steady consumption, but localized shortages could arise from raw‑material constraints. Key risk factors include regulatory tightening on off‑label use, pricing reforms in major markets, and potential supply chain disruptions linked to geopolitical tensions. Decision‑makers should monitor patent‑expiry timelines and emerging combination therapies to capitalize on growth pockets.

11 items

1. Executive Summary

2. Bicalutamide Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Bicalutamide Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Bicalutamide Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Single Drug For Prostate Cancer

6.1.2. Combined Chemotherapy For Prostate Cancer

6.1.3. Combined Radiation Therapy Or Castration For Prostate Cancer

6.2. Global Bicalutamide Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Tablets

6.2.2. Capsule

6.3. Global Bicalutamide Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Bicalutamide Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Bicalutamide Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Bicalutamide Market Competition by Key Manufacturers

8.1. Global Bicalutamide Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Bicalutamide: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AstraZeneca

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. CORDEN PHARMA GMBH

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Zeneca GmbH

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Actavis Pharma

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sivem Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Sorres Pharma

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Fresenius Kabi

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. ANI Pharmaceuticals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Accel Pharma

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Apotex Corporation

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Shanghai Fudan Fuhua Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Shanghai Zhaohui Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Zhejiang Haizheng Pharmaceutical

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Shanxi Zhendong Pharmaceutical

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Bicalutamide Market

Figure 4: Global Bicalutamide Market: Drivers

Figure 5: Global Bicalutamide Market: Challenges

Figure 6: Global Bicalutamide Market: Trends

Figure 7: Global Bicalutamide Market: Opportunity

Figure 8: Global Bicalutamide Market: Restraint

Figure 9: Global Bicalutamide Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Bicalutamide Market Value (USD Million) By Region

Figure 15: Global Bicalutamide Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Bicalutamide Market Value (USD Million) By Region

Figure 23: Global Bicalutamide Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Bicalutamide Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Bicalutamide Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Bicalutamide Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Bicalutamide Market Value (USD Million) By Region

Table 10: Global Bicalutamide Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Bicalutamide Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Bicalutamide Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Bicalutamide Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AstraZeneca Basic Information And Sales Area

Table 31: AstraZeneca. Products Portfolio

Table 32: CORDEN PHARMA GMBH Basic Information And Sales Area

Table 33: CORDEN PHARMA GMBH. Products Portfolio

Table 34: Zeneca GmbH Basic Information And Sales Area

Table 35: Zeneca GmbH. Products Portfolio

Table 36: Actavis Pharma Basic Information And Sales Area

Table 37: Actavis Pharma. Products Portfolio

Table 38: Sivem Pharmaceuticals Basic Information And Sales Area

Table 39: Sivem Pharmaceuticals. Products Portfolio

Table 40: Sorres Pharma Basic Information And Sales Area

Table 41: Sorres Pharma. Products Portfolio

Table 42: Fresenius Kabi Basic Information And Sales Area

Table 43: Fresenius Kabi. Products Portfolio

Table 44: ANI Pharmaceuticals Basic Information And Sales Area

Table 45: ANI Pharmaceuticals. Products Portfolio

Table 46: Accel Pharma Basic Information And Sales Area

Table 47: Accel Pharma. Products Portfolio

Table 48: Apotex Corporation Basic Information And Sales Area

Table 49: Apotex Corporation. Products Portfolio

Table 50: Shanghai Fudan Fuhua Pharmaceutical Basic Information And Sales Area

Table 51: Shanghai Fudan Fuhua Pharmaceutical. Products Portfolio

Table 52: Shanghai Zhaohui Pharmaceutical Basic Information And Sales Area

Table 53: Shanghai Zhaohui Pharmaceutical. Products Portfolio

Table 54: Zhejiang Haizheng Pharmaceutical Basic Information And Sales Area

Table 55: Zhejiang Haizheng Pharmaceutical. Products Portfolio

Table 56: Shanxi Zhendong Pharmaceutical Basic Information And Sales Area

Table 57: Shanxi Zhendong Pharmaceutical. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global Bicalutamide Market Value (USD Million) By Region

Table 63: Global Bicalutamide Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

FAQs

1. What is the current Bicalutamide market size?

The Bicalutamide market size reached roughly USD 1.3 billion in 2023, reflecting sales of generic and branded formulations across oncology and urology segments, globally. North America contributed the largest share, driven by entrenched treatment protocols for advanced prostate cancer market.

2. What is the projected growth rate for the Bicalutamide market?

Forecasts anticipate a compound annual growth rate of 5.2 % between 2024 and 2032, expanding the market to about USD 2.1 billion by 2032, propelled by rising prostate‑cancer incidence, expanding generic adoption, and emerging economies strengthening therapeutic pipelines.

3. Which factors are driving the Bicalutamide market?

Key drivers include increasing prevalence of advanced prostate cancer, favorable cost‑effectiveness of oral anti‑androgen therapy, expanding insurance coverage, and the shift toward combination regimens with novel hormonal agents, all supporting higher prescription volumes worldwide in the coming decade.

4. What are the main challenges facing the Bicalutamide market?

Challenges comprise patent expirations that intensify generic competition, pricing pressures from health‑care payers, limited differentiation among oral anti‑androgens, and emerging safety concerns regarding hepatic toxicity, which together constrain profit margins and market expansion for manufacturers in the near term.

5. Which regions are leading the Bicalutamide market?

North America remains the dominant region, accounting for roughly 45 % of global sales, driven by high prostate‑cancer prevalence and reimbursement structures. Europe follows with strong generic uptake, while Asia‑Pacific shows rapid growth due to expanding oncology infrastructure.

6. Who are the top companies competing in the Bicalutamide market?

Leading players include AstraZeneca, which holds the original brand‑named “Casodex,” Teva Pharmaceutical, Sun Pharma, Mylan (now Viatris), and Cipla, each leveraging extensive generic portfolios and strategic partnerships to maintain market share amid intensifying competition.

7. What future opportunities exist for the Bicalutamide market?

Opportunities arise from combination therapies with next‑generation androgen receptor inhibitors, expansion into earlier‑stage disease settings, development of fixed‑dose combos to improve adherence, and potential entry into emerging markets where prostate‑cancer screening programs are being established.

8. How is technology influencing the Bicalutamide market?

Digital health platforms enable remote monitoring of treatment response, while AI‑driven analytics assist physicians in selecting optimal anti‑androgen regimens. Additionally, advanced manufacturing technologies improve bioavailability and reduce production costs, supporting broader market penetration for patients globally.

9. What is the regulatory landscape for Bicalutamide worldwide?

Bicalutamide is approved in most major markets as a prescription‑only drug, with generic pathways accelerated under Hatch‑Waxman in the U.S. and EMA’s centralized procedure in Europe, while emerging economies are tightening oncology drug review timelines.

Contact for Full Report

Loading report content...

Bicalutamide Industry Trends & Competitive Analysis 2033

Market Snapshot

Bicalutamide Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Bicalutamide Segmentation

Bicalutamide Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Bicalutamide market size?

2. What is the projected growth rate for the Bicalutamide market?

3. Which factors are driving the Bicalutamide market?

4. What are the main challenges facing the Bicalutamide market?

5. Which regions are leading the Bicalutamide market?

6. Who are the top companies competing in the Bicalutamide market?

7. What future opportunities exist for the Bicalutamide market?

8. How is technology influencing the Bicalutamide market?

9. What is the regulatory landscape for Bicalutamide worldwide?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Bicalutamide Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Bicalutamide Segmentation

Bicalutamide Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Bicalutamide market size?

2. What is the projected growth rate for the Bicalutamide market?

3. Which factors are driving the Bicalutamide market?

4. What are the main challenges facing the Bicalutamide market?

5. Which regions are leading the Bicalutamide market?

6. Who are the top companies competing in the Bicalutamide market?

7. What future opportunities exist for the Bicalutamide market?

8. How is technology influencing the Bicalutamide market?

9. What is the regulatory landscape for Bicalutamide worldwide?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation